Strasbourg, France, 16–20 July 2025 —The Society of Robotic Surgery (SRS 2025), one of the field’s most influential academic events, brought together surgical experts from over 20 countries. MicroPort® MedBot™ (MedBot™) made a strong impression with a comprehensive showcase featuring remote surgery innovations, live cross-border procedures, expert sessions, and hands-on demonstrations.
With two groundbreaking live-streamed cross-continental procedures, the world’s first ultra-remote liver resection and the first transcontinental prostatectomy between Europe and Asia, MedBot™ once again pushed the boundaries of what is possible in remote robotic surgery.
During the conference, MedBot™ presented its most comprehensive product lineup: Toumai® Multi-port Laparoscopic Surgical Robot, Toumai® Single-port Laparoscopic Surgical Robot, SkyWalker® Orthopedic Surgical Robot, R-ONE® Vascular Intervention Robot, DFVision® 3D Electronic Laparoscope. Each system attracted significant attention for its clinical performance, versatility, and integration of advanced technologies for remote operation.
Global Collaboration: Enabling Surgical Innovation Without Borders
MedBot™ drew strong interest for its precision, operability, and innovative approach to surgical care. Nearly a thousand surgeons, researchers, and industry leaders visited the booth for first-hand experience.
The Toumai® Multi-port Surgical Robot stood out for its stable arms, HD 3D imaging, and versatile instruments, earning praise for its adaptability across urology, general surgery, thoracic, and gynecology - and as the first remote-capable surgical robot approved for clinical use by April 2025.
Making its international debut, the Toumai® Single-port Systemfeatures a dual “C-arm” architecture combined with high-flexibility snake-like instruments, enabling precision in tight spaces and wide-range multi-quadrant operations.
The SkyWalker® Orthopedic Surgical Robot showcased precision in knee replacements through AI-assisted intraoperative adjustments and accurate pre-op planning.
The R-ONE®Vascular Intervention Robot demonstrated fine control for remote vascular navigation, improving safety and accuracy.
The DFVision® 3D Electronic Laparoscope offered surgeons immersive 3D views and HD dual imaging for rapid, precise targeting.
Beyond the exhibit, MedBot™ hosted 26 academic sessions, including 3 live and semi-live telesurgeries, 1 lunch symposium, and 22 keynote lectures and discussions, demonstrating our strength across urology, general surgery, thoracic surgery, gynecology, orthopedics, and cardiovascular intervention, demonstrating its strengths across multiple specialties and its mission to “Make Surgery Easier, Safer, and Less Invasive”.
Historic Intercontinental Telesurgeries
MedBot™ set two new world records at SRS 2025:
Record 1: Liver Resection Across 10,000 Kilometers
On July 19, Dr. Liang Xiao from Zhejiang University’s Sir Run Run Shaw Hospital, performed the world’s first cross-continental ultra-remote liver resection using the Toumai® Multi-port Robot. Operating from Strasbourg, he successfully removed the left lobe of the liver from an 80-year-old patient in Hangzhou, China. Despite the patient’s complex surgical history, the 50-minute procedure ran smoothly with stable system performance and clear, low-latency transmission.
Record 2: Transcontinental Prostatectomy
On July 16, Dr. Saad Aldousari remotely performed a radical prostatectomy from Strasbourg on a patient in Kuwait City using the Toumai® system. The surgery took under two hours, with network latency peaking at just 106ms. Moderated by remote surgery pioneer Dr. Youness Ahallal, the procedure was broadcast live to over 2,500 SRS attendees. Kuwait’s Health Minister, Dr. Ahmed Al-Awadhi, attended on-site and endorsed the country’s telemedicine progress. Local media hailed the operation as a national milestone.
It marked Dr. Aldousari’s ninth international robotic surgery with the Toumai® system.
Building a Global Surgical Ecosystem with IRCAD
On the opening day of the conference, MedBot™ and IRCAD, the world-renowned training and research center for minimally invasive surgery, jointly inaugurated a dedicated Toumai® Robotics Training Center in Strasbourg.
Guests of honor included Professor Jacques Marescaux, IRCAD founder and pioneer of remote surgery (notably the 2001 Lindbergh Operation), MedBot™ President Dr. Chao He, and Jonathan Chen, Co-CEO of MicroPort®. Professor Marescaux’s presence symbolized the fusion of remote surgery’s historic breakthroughs with its future-driven innovation.
The center will serve as a platform for global training, academic collaboration, and clinical research.
Making Remote Surgery Routine: Infrastructure, Policy, and Talent
In his keynote, Dr. Chao He emphasized that remote surgery is not just a technical breakthrough, but a transformation of the healthcare system. He called for alignment across policy, training, and standards to support broader adoption, likening top surgical talent to world-class athletes.
Since receiving regulatory approval in April, the Toumai® system became the first remote-capable surgical system authorized for clinical use globally, setting a benchmark for regulatory and clinical frameworks in tele-surgery. Experts at the conference echoed this vision: remote surgery decentralizes expertise, addresses workforce gaps, and gains flexibility as training systems mature. Future applications, Dr. He noted, will extend beyond urology to fields like cardiology and neurology, where time is critical.
400+ Remote Surgeries, 40+ Global Records
Since 2022, the Toumai® system has been used in over 400 remote surgeries with a 100% success rate, achieving more than 40 world records. The system has demonstrated reliability across multiple network configurations, including 5G private lines, public 5G, broadband, geostationary satellites, and low Earth orbit satellite internet.
Dr. He concluded: “A new wave of medical innovation, led by 5G-enabled remote robotics and AI, is reshaping healthcare. MedBot™ will continue to lead through open collaboration, drive breakthroughs in surgical robotics, and accelerate the global shift toward smarter, more accessible surgical care”.
About MicroPort® MedBot™
Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort® MedBot™", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort®", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort® MedBot™, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.
More information is available at: www.medbotsurgical.com/en